TY - JOUR
T1 - Risks and benefits of available treatments for adult ADHD.
AU - Newcorn, Jeffrey H.
PY - 2011/3
Y1 - 2011/3
N2 - Several pharmacotherapeutic options, both FDA-approved and off-label, exist for the treatment of adult ADHD. The most commonly used agents include several stimulants and atomoxetine, which have demonstrated significant, though similar, efficacy for ADHD versus placebo. Treatment should be selected according to patient comorbidity profiles, cardiovascular risks, and risk of abuse of prescription medications. In this activity, treatments for ADHD with and without comorbidity are discussed, including mechanisms of action, safety risks, and the potential for substance abuse. Implementing psychosocial education in conjunction with pharmacotherapy is recommended.
AB - Several pharmacotherapeutic options, both FDA-approved and off-label, exist for the treatment of adult ADHD. The most commonly used agents include several stimulants and atomoxetine, which have demonstrated significant, though similar, efficacy for ADHD versus placebo. Treatment should be selected according to patient comorbidity profiles, cardiovascular risks, and risk of abuse of prescription medications. In this activity, treatments for ADHD with and without comorbidity are discussed, including mechanisms of action, safety risks, and the potential for substance abuse. Implementing psychosocial education in conjunction with pharmacotherapy is recommended.
UR - http://www.scopus.com/inward/record.url?scp=79957751525&partnerID=8YFLogxK
U2 - 10.4088/JCP.9066tx2c
DO - 10.4088/JCP.9066tx2c
M3 - Comment/debate
C2 - 21450148
AN - SCOPUS:79957751525
SN - 0160-6689
VL - 72
SP - e12
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - 3
ER -